Polyclonal Rabbit IL20RB Antibody
- Known as:
- Polyclonal Rabbit IL20RB Antibody
- Catalog number:
- KA1768
- Product Quantity:
- 100ul
- Category:
- -
- Supplier:
- KareBay
- Gene target:
- Polyclonal Rabbit IL20RB Antibody
Related genes to: Polyclonal Rabbit IL20RB Antibody
- Gene:
- IL20RB NIH gene
- Name:
- interleukin 20 receptor subunit beta
- Previous symbol:
- FNDC6
- Synonyms:
- DIRS1, IL-20R2, MGC34923
- Chromosome:
- 3q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 2000-05-23
- Date modifiied:
- 2015-12-11
Related products to: Polyclonal Rabbit IL20RB Antibody
Related articles to: Polyclonal Rabbit IL20RB Antibody
- Head and neck squamous cell carcinoma (HNSC) exhibits substantial prognostic and microenvironmental heterogeneity. However, the integrated prognostic relevance of synergistic immune and inflammatory signatures in HNSC remains fully elucidated. - Source: PubMed
Publication date: 2026/06/19
Li JieSun ShuxianJi ZiyuWang JiaTang SichenShen ShuijieShi Xiaoya - Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinomas and is known for having the worst prognosis. It features a complex array of histone deacetylases (HDACs), which play varied roles in tumor progression and patient outcomes. Exploring the role and significance of HDACs in ccRCC can provide effective prognosis and treatment methods for ccRCC. - Source: PubMed
Publication date: 2026/05/23
Yuehua LiDong XingyouGuiqiang LiFeiqiang RenBin XuWei TanJie WangYu Guo - IL20RB, interleukin 20 receptor subunit beta, functions as a cytokine receptor subunit coding gene and has been discovered to serve an essential function in human malignancies. However, the link between IL20RB expression, clinical outcomes, and tumor-infiltrating lymphocytes in clear cell renal cell carcinoma (ccRCC) remains unclear. - Source: PubMed
Publication date: 2026/03/10
Liu YufengXie YingminYan LingfeiLuo YangLiu DaweiLi QingXu WuWang Tao - BACKGROUND: The progression of colorectal cancer (CRC) is profoundly shaped by immune and metabolic dysregulation within the tumor microenvironment (TME). This study aimed to develop an immune–metabolism-related gene (IMRG)-based prognostic model and experimentally validate its key molecular drivers. METHODS: Transcriptomic and clinical data from the TCGA and GEO cohorts were analyzed to identify differentially expressed IMRGs. Molecular subtypes were defined using non-negative matrix factorization (NMF) clustering, and a machine learning–based prognostic model integrating 101 algorithmic combinations was constructed and validated. Gene Set Enrichment Analysis (GSEA), immune infiltration profiling, and drug sensitivity analyses were performed to elucidate biological and immunological differences. IL20RB, identified as a hub IMRG, was further validated through qRT–PCR, Western blotting, and IHC. Its functional role was assessed using CCK-8, wound-healing, and Transwell assays. RESULTS: NMF clustering revealed two distinct molecular subtypes of CRC with divergent survival outcomes and immune characteristics. The 4-gene IMRG-based model demonstrated robust prognostic performance (C-index = 0.657) and was externally validated in a GEO cohort (AUC up to 0.824 for 1-, 3-, and 5-year survival). GSEA showed that the high-risk group was enriched for complement/coagulation cascades and extracellular matrix remodeling, whereas the low-risk group was enriched for metabolic programs including butanoate metabolism and the TCA cycle. Immune profiling indicated increased CD8⁺ T-cell infiltration in the high-risk group and a distinct immune checkpoint landscape, with most checkpoints elevated in the low-risk group, while ADORA2A, TNFRSF25 and CD276 were relatively higher in the high-risk group. Experimental analyses confirmed that IL20RB was significantly upregulated in CRC tissues and cell lines, and its silencing markedly inhibited CRC cell proliferation, migration, and invasion, consistent with its predicted oncogenic role. CONCLUSION: This integrative transcriptomic and computational analysis combined with machine learning and experimental validation identified IMRGs—particularly IL20RB—as critical mediators of CRC progression. The proposed IMRG-based prognostic model offers a robust framework for patient risk stratification, immune landscape characterization, and therapeutic targeting in CRC. - Source: PubMed
Publication date: 2026/03/03
Sun ZhanyuanWang ZijingLv QingchenHou ShaohuaLi GuoJiang TaoLi Hai - Colorectal cancer (CRC) exhibits substantial prognostic heterogeneity, and immune checkpoint inhibitors benefit only approximately 10%-15% of patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) status. Therefore, there is an urgent need for risk stratification tools that are both biologically interpretable and clinically applicable. - Source: PubMed
Publication date: 2026/02/24
Cao JinzhongHou ShaohuaWang ZijingSun ZhanyuanChang XinChen XiLv HengyiJiang TaoLi Hai